ArticleBMC geriatrics2026
Association of a new TyG indicator, TyHGB, with cardiovascular disease incidence among the elderly: evidence from a prospective cohort study.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCVDs remain a major global public health concern, highlighting the need for simple and effective screening tools. Current evidence regarding the association between TyHGB and CVDs were limited. This study aims to investigate the association between TyHGB and CVDs among the elderly using data from a large community-based cohort study.
methodThis study utilized data from the BaHLS involving elderly individuals in Shenzhen, China. The TyHGB value was calculated using the following formula: TyHGB = TG/HDL-C + 0.7 × FBG (mmol/L) + 0.1 × BMI (kg/m²). A multivariate Cox proportional hazards model and a RCS model were employed to assess the longitudinal association between TyHGB and CVDs.
resultsA total of 26,603 subjects were included in the study, of whom 1,968 (7.40%) experienced CVD events during the follow-up period. After adjusting for confounding factors, we found that for per 1-SD increase in TyHGB, the HRs for overall CVDs, stroke, and AMI were 1.12 (95% CI: 1.07-1.16), 1.09 (95% CI: 1.04-1.15), and 1.30 (95% CI: 1.24-1.37), respectively. After stratification by baseline TyHGB quartiles, higher TyHGB levels were associated with increased risks of overall CVDs, stroke, and AMI, with HRs of 1.35 (95% CI: 1.15-1.56), 1.23 (95% CI: 1.03-1.47), and 1.72 (95% CI: 1.33-2.21), respectively; these significant associations were consistent in subgroup analysis. RCS models revealed a linear association between TyHGB and risks of overall CVDs, stroke, and AMI (nonlinear test, P > 0.05).
conclusionTyHGB demonstrates a significant longitudinal association with CVDs events among the elderly. Derived from routine clinical laboratory parameters, TyHGB represents a promising tool for CVDs risk stratification and prevention in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.